To include your compound in the COVID-19 Resource Center, submit it here.

Arcturus fails to nominate FY17 statement auditor

Arcturus Therapeutics Ltd. (NASDAQ:ARCT) said its shareholders did not ratify the appointment of Ernst

Read the full 141 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE